JP2013523892A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523892A5
JP2013523892A5 JP2013505098A JP2013505098A JP2013523892A5 JP 2013523892 A5 JP2013523892 A5 JP 2013523892A5 JP 2013505098 A JP2013505098 A JP 2013505098A JP 2013505098 A JP2013505098 A JP 2013505098A JP 2013523892 A5 JP2013523892 A5 JP 2013523892A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
retinal
oil
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013505098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/032325 external-priority patent/WO2011130411A1/en
Publication of JP2013523892A publication Critical patent/JP2013523892A/ja
Publication of JP2013523892A5 publication Critical patent/JP2013523892A5/ja
Pending legal-status Critical Current

Links

JP2013505098A 2010-04-15 2011-04-13 視覚障害を処置するための組成物および方法 Pending JP2013523892A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32463210P 2010-04-15 2010-04-15
US61/324,632 2010-04-15
PCT/US2011/032325 WO2011130411A1 (en) 2010-04-15 2011-04-13 Compositions and methods for treating visual disorders

Publications (2)

Publication Number Publication Date
JP2013523892A JP2013523892A (ja) 2013-06-17
JP2013523892A5 true JP2013523892A5 (cg-RX-API-DMAC7.html) 2014-05-29

Family

ID=44009992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013505098A Pending JP2013523892A (ja) 2010-04-15 2011-04-13 視覚障害を処置するための組成物および方法

Country Status (8)

Country Link
US (1) US20110257186A1 (cg-RX-API-DMAC7.html)
EP (1) EP2558100A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013523892A (cg-RX-API-DMAC7.html)
KR (1) KR20130092976A (cg-RX-API-DMAC7.html)
AU (1) AU2011239683A1 (cg-RX-API-DMAC7.html)
CA (1) CA2796345A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012148214A (cg-RX-API-DMAC7.html)
WO (1) WO2011130411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600127037A1 (it) * 2016-12-15 2018-06-15 Oftalab S R L Soluzione oftalmica di verde di lissamina e suo uso in oftalmologia
CN109908327A (zh) * 2019-03-12 2019-06-21 广州陈锦济生物科技有限公司 一种用于治疗近视的眼药水及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
PL378366A1 (pl) * 2003-01-13 2006-04-03 Cortex Pharmaceuticals, Inc. Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem
EP2010174A4 (en) * 2006-04-20 2012-05-09 Univ California PHARMACOLOGICAL MODULATION OF POSITIVE AMPA-RECEPTOR MODULATOR EFFECT ON NEUROTROPHINEXPRESSION
US20080139472A1 (en) * 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
ZA200904826B (en) * 2007-01-03 2010-09-29 Cortex Pharma Inc 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
CA2674321A1 (en) 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
NZ584098A (en) * 2007-09-20 2012-05-25 Cortex Pharma Inc 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Similar Documents

Publication Publication Date Title
CA3045733C (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
JP2019514956A5 (cg-RX-API-DMAC7.html)
JP2009511632A5 (cg-RX-API-DMAC7.html)
JP2017537985A5 (cg-RX-API-DMAC7.html)
JP2018529693A5 (cg-RX-API-DMAC7.html)
RU2005118107A (ru) Ингибиторы гистондеацетилазы для лечения офтальмологических неоваскулярных или отечных нарушений и заболеваний
JP2018536648A5 (cg-RX-API-DMAC7.html)
JP2015523546A5 (cg-RX-API-DMAC7.html)
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
JP2015025011A5 (cg-RX-API-DMAC7.html)
WO2012047966A3 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
JP2019055988A5 (ja) 治療用化合物および医薬組成物
HRP20220138T1 (hr) Peptidni pripravci i postupci uporabe
JP2018514590A5 (cg-RX-API-DMAC7.html)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
JP2017525758A5 (cg-RX-API-DMAC7.html)
AU2015205188A1 (en) Pharmaceutical preparation containing pyridylamino acetic acid compound
MX2021005077A (es) Peptidos y composiciones farmaceuticas para tratar enfermedades oculares.
HRP20190561T1 (hr) Postupci liječenja bolesti oka povezanih s upalom i vaskularnom proliferacijom
JP2021521178A5 (cg-RX-API-DMAC7.html)
JP2010514733A5 (cg-RX-API-DMAC7.html)
JP2023503898A5 (cg-RX-API-DMAC7.html)
RU2009128968A (ru) Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами
JP2015083565A5 (cg-RX-API-DMAC7.html)